Capital Berg

Keeps People Up-To-Date

Wednesday, January 27, 2021
Log in
  • United States
  • Business
  • Health
  • Science
  • Technology
  • About CapitalBerg
    • Analysts & Contributors
    • Advertising
    • Contact US
    • Privacy Policy GDPR
    • Terms of Use

Pages

  • About CapitalBerg
  • Advertising
  • Analysts & Contributors
  • Contact US
  • Investor Relations
  • Privacy Policy GDPR
  • SEC Disclosure
  • Terms of Use

Recent Posts

  • Tennessee Rapist Breaks into Woman’s House Three Times the Same Night to Assault Her June 29, 2018
  • Mentally Ill Man Arrested After Breaking into Retirement Home to Grope a Woman’s Chest June 28, 2018
  • “Syndrome” Author Blake Leibel Sentenced to Life in Prison for the Murder and Torture of Girlfriend June 27, 2018
  • Michigan Dad to Be Sentenced in the Beating Death of 3-Year-Old Infant June 26, 2018
  • Ohio Patrolman Booted from Police After Pulling Over His Daughter and Boyfriend June 26, 2018
  • Utah Mayor Shares Heartwarming Letter of Man Apologizing for Stealing a Stop Sign 75 Years Ago June 25, 2018
  • Mississippi Man Beheaded Mother After A Spat over Credit Cards June 25, 2018

Pfizer Proven Miracle To Fight Against ROS1 Lung Cancer Through Xalkori

September 28, 2014 By Marlene R. Litten

Pfizer-xalkori-helpful-for-lung-cancer

In annual congress of European Society for Medical Oncology (ESMO) in Madrid the researchers presented the study describing Xalkori as a wonder drug. The drug Xalkori manufactured by Pfizer Incorporation is new in the market and is made to treat a rare type of lung cancer- the non small cell lung cancer (NSCLC). A clinical trial has shown surprising effects of Xalkori in reducing the size of this tumour and can be an effective treatment for people suffering from this uncommon form of illness related to gene defect.

The lead investigator Dr. Alice Shaw, from Boston’s Massachusetts General Hospital Cancer Center, reported that this clinical trial is the first solid study to establish crizotinib’s activity in victims of lung cancer who are tested positive for ROS1 and confirms that ROS1 is an authentic therapeutic target in those patients.

The database of the study involved 50 individuals diagnosed with NSCLC with a mutation in ROS1 gene. Out of 50, 36 patients consuming the drug showed shrinkage in the tumor size. This made a remarkable conclusion of 72 percent people benefiting from Pfizer medication through reduction in their fatal tumors. Moreover intake of Xalkori on a regular basis can actually halt the progression of the disease. This halt in the tumor growth was noted in nine patients.

Dr. Shaw in a separate statement stated that resistance with Xalkori develops much later as compared to other therapies used for treating lung cancers or melanoma.

Xalkori, with chemical name crizotinib, is approved from the US Centre for Disease Control and Prevention (CDC) for treating people with NSCLC having ALK fusion gene resulting from a mutation. This defective alteration in the genetic constituent of ALK plays a critical role in the growth of NSCLC; the same thing is witnessed in ROS 1 gene mutation too. However the clinical trial focused on the lung cancer due to rearrangements in ROS 1 gene only.

The medicine also serves spot diagnosis for detecting mutation in the ALK protein that occurs in 4 percent of individuals suffering from the disease. One important thing that should be kept in mind is that this Pfizer medication has longer duration of action, if taken twice daily, the medicine shows response within 17 month approximately.

Filed Under: Health Tagged With: Boston’s Massachusetts General Hospital Cancer Center, crizotinib, Dr. Alice Shaw, lung cancers, melanoma, NSCLC, Pfizer, ros 1 gene, Xalkori

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 44 other subscribers

Recent Articles

sleep

Tennessee Rapist Breaks into Woman’s House Three Times the Same Night to Assault Her

June 29, 2018 By Denise Ehrlich Leave a Comment

police lights

Mentally Ill Man Arrested After Breaking into Retirement Home to Grope a Woman’s Chest

June 28, 2018 By Waleed Javed Leave a Comment

gavel

“Syndrome” Author Blake Leibel Sentenced to Life in Prison for the Murder and Torture of Girlfriend

June 27, 2018 By Andreas Petersen Leave a Comment

Woods

Michigan Dad to Be Sentenced in the Beating Death of 3-Year-Old Infant

June 26, 2018 By Marlene R. Litten Leave a Comment

patrol cruiser

Ohio Patrolman Booted from Police After Pulling Over His Daughter and Boyfriend

June 26, 2018 By Waleed Javed Leave a Comment

stop sign

Utah Mayor Shares Heartwarming Letter of Man Apologizing for Stealing a Stop Sign 75 Years Ago

June 25, 2018 By June Harris Leave a Comment

Butter knives

Mississippi Man Beheaded Mother After A Spat over Credit Cards

June 25, 2018 By Carol Harper Leave a Comment

XXXTentacion mugshot

Florida Authorities Arrested Suspect in Connection with Shooting of XXXTentacion

June 22, 2018 By Waleed Javed Leave a Comment

sunset over beach

Dallas Mother Accused of Beating Four-Year-Old and Dumping Body Into the Water

June 21, 2018 By Denise Ehrlich Leave a Comment

chicken Alfredo

Ohio Man Sentenced for Trying to Seduce Teenage Boy with Naked Pictures and Chicken Alfredo

June 20, 2018 By Marlene R. Litten Leave a Comment

bedroom

South Carolina Teen and Mates End Up In Slammer for Raping a Teenage Girl

June 19, 2018 By Waleed Javed Leave a Comment

cyberstalkin

California Man Arrested for Stalking Ex-Girlfriend, Hacking Her Online Accounts

June 19, 2018 By June Harris Leave a Comment

hammer

Naked Patient Sneaks out of Emergency Room to Bash Homeowner’s Head with Hammer

June 18, 2018 By Carol Harper Leave a Comment

screwdriver

Middle School Student Attacks Teacher During Class with Screwdriver

June 18, 2018 By Andreas Petersen Leave a Comment

Categories

  • Business
  • Deals
  • Health
  • Science
  • Technology
  • United States
  • World

Copyright © 2021 capitalberg.com

About · Privacy Policy · Terms of Use · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.